Changing the course of peripheral arterial disease using adult stem progenitor cells

Mark Niven, Galit Sivak, Shlomo Baytner, Roman Liberson, Shlomo Bulvik, Yael Porat*, Michael Frogel, Louis Shenkman, Martin Grajower, Frank Veith, Michael Belkin

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


Lower extremity arterial disease affects more than 200 x 10e6 people worldwide causing Critical Limb Ischemia (CLI), also referred to as chronic limb-threatening ischemia (CLTI) a life-threatening disease and the major cause of ischemic amputation. For nonrevascularizable patients, the outlook is bleak and novel therapies are needed. This chapter discusses new approaches including gene therapy and stem/progenitor cell (SPC)-based therapies, including autologous bone marrow-derived cells (BM), MB-mononuclear cells (BM-MNC), mesenchymal stem cells (MSC), mobilized bone marrow cell (PB-MNC), allogeneic cells and ex vivo expanded or activated/differentiated cell products. A preliminary first-in-human trial of a novel treatment is presented that combines immune cell therapy and a stepwise activation and differentiation of SPC. Cells from a standard blood draw (with no pretreatment or mobilization) are transformed, within a day, into a therapeutic product (BGC101) composed of endothelial progenitor cells (EPCs), SPCs, dendritic cells (DCs), and T helper cells. BGC101 was found safe and effective in stabilizing and reversing the course of CLI. Controlled studies on a larger population are planned to evaluate this new concept.

Original languageEnglish
Title of host publicationStem Cell Therapy for Vascular Diseases
Subtitle of host publicationState of the Evidence and Clinical Applications
PublisherSpringer International Publishing
Number of pages36
ISBN (Electronic)9783030569549
ISBN (Print)9783030569532
StatePublished - 5 Nov 2020


  • Critical limb ischemia, chronic limb threatening ischemia, diabetes complications
  • Dendritic cells
  • Endothelial progenitor cells, bone marrow cells, mesenchymal stem cells
  • Peripheral artery disease
  • Regenerative medicine, personalized cell therapies
  • Stem/progenitor cells therapy


Dive into the research topics of 'Changing the course of peripheral arterial disease using adult stem progenitor cells'. Together they form a unique fingerprint.

Cite this